ライフサイエンスコーパス: LABA

1 LABA step-up was significantly more likely to provide th

2 97.1% used ICS (dose 2000 BDP), 93.6% LABA in association with ICS, 53.3% LTRAs, 64.1% anti-Ig

3 dults with asthma treated with ICS, adding a LABA did not improve time to asthma exacerbation compare

4 The use of a LABA but not an LTRA as an "add-on controller" is associ

5 were established as follows: (1) users of a LABA plus low-dose ICS combination or users of a medium-

6 the other subcohort included 198 users of a LABA plus medium-dose ICS and 156 users of a high-dose I

7 sers of a medium-dose ICS and (2) users of a LABA plus medium-dose ICS combination or users of a high

8 alformations in asthmatic women exposed to a LABA plus ICS combination and those exposed to ICS monot

9 ne subcohort there were 643 women who used a LABA plus low-dose ICS and 305 who used a medium-dose IC

10 lformations was 1.1 (95% CI, 0.6-1.9) when a LABA plus low-dose ICS was used compared with a medium-d

11 um-dose ICS and 1.2 (95% CI, 0.5-2.7) when a LABA plus medium-dose ICS was used compared with a high-

12 orticosteroid alone or in combination with a LABA alters protein and gene expression pathways associa

13 sk of major malformations was similar with a LABA plus ICS combination and ICS monotherapy at higher

14 The role of treatment with a LABA-LAMA regimen in these patients is unclear.

15 roate (FF) and long-acting beta(2) -agonist (LABA) vilanterol (VI) on early and late asthmatic respon

16 -up therapy) or long-acting beta(2)-agonist (LABA step-up therapy).

17 nclude adding a long-acting beta(2)-agonist (LABA) or increasing the ICS dose.

18 ng a long-acting beta2-adrenoceptor agonist (LABA)/ICS combination therapy, we tested the hypothesis

19 nts associated with longacting beta agonist (LABA) use have caused the US Food and Drug Administratio

20 16 amino acid) and long-acting beta-agonist (LABA) exposure for asthma exacerbations in children.

21 recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting mu

22 Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asthma

23 ticosteroid (ICS)/long-acting beta2-agonist (LABA) therapy in patients with chronic obstructive pulmo

24 g-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the bronchial epithelium are unknown.

25 =600 mug/day], and long-acting beta-agonist [LABA] use [yes/no]).

26 d long-acting beta2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of

27 Long-acting beta2-agonists (LABA) and leukotriene receptor antagonists (LTRA) are tw

28 Long-acting beta2-agonists (LABA) were shown to inhibit LPS-induced bronchial inflam

29 oids (ICS) and long-acting beta(2)-agonists (LABAs) are recommended in patients with asthma that is n

30 adding inhaled long-acting beta(2)-agonists (LABAs) to corticosteroids in asthma.

31 ns of long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) pr

32 by long-acting beta2-adrenoceptor agonists (LABAs) and may contribute to the clinical superiority of

33 , long-acting beta(2)-adrenoceptor agonists (LABAs) given twice daily cause the same degree of bronch

34 luded 2 trials of long-acting beta-agonists (LABAs) (n = 3174), 1 RCT of LABAs and inhaled corticoste

35 ppropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debat

36 rround the use of long-acting beta-agonists (LABAs) for the treatment of asthma, even in combination

37 acy and safety of long-acting beta-agonists (LABAs) have been questioned.

38 Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-re

39 o the addition of long-acting beta-agonists (LABAs) to ICSs.

40 cocorticoids plus long-acting beta-agonists (LABAs).

41 ucocorticoids and long-acting beta-agonists (LABAs).

42 rapy with/without long-acting beta-agonists (LABAs).

43 atment response to longacting beta-agonists (LABAs).

44 led therapy with long-acting beta2 agonists (LABAs) and corticosteroids is beneficial in treating ast

45 associated with long-acting beta2-agonists (LABAs) have led to many US Food and Drug Administration

46 substitute the combination of an LTRA and an LABA for the combination of inhaled corticosteroid and a

47 combination of inhaled corticosteroid and an LABA.

48 adequately controlled with high-dose ICS and LABA therapy.

49 ay be a synergistic benefit between LAMA and LABA as a consequence of receptor cross-talk, which in t

50 ta(2)-adrenergic receptor agonists (SABA and LABA, respectively) relieve asthma symptoms, use of eith

51 levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was

52 spite the use of inhaled glucocorticoids and LABAs, the addition of tiotropium significantly increase

53 o were receiving inhaled glucocorticoids and LABAs, we compared the effect on lung function and exace

54 Among the approved LABA, indacaterol has a 24 h duration of action, whereas

55 In asthma, LABAs enhance glucocorticoid receptor (GR) nuclear trans

56 However, because LABAs are given twice daily but tiotropium bromide is re

57 There was no difference between LABA + ICS vs tiotropium + ICS in time to first exacerba

58 erlie the complementary interactions between LABAs and corticosteroids, although the precise signal t

59 ations may be disproportionately affected by LABA risks.

60 gulation and associated tolerance induced by LABA.

61 The elements of asthma control achieved by LABAs (improved lung function) and leukotriene receptor

62 the superior clinical effects of combination LABA/corticosteroid treatment compared with either as mo

63 Newly prescribed combination LABAs and inhaled corticosteroids or LABAs alone.

64 New once-daily LABA, including vilanterol, olodaterol, milveterol, carm

65 ce-daily tiotropium (n = 532) or twice-daily LABAs (n = 538,) and were followed up for up to 18 month

66 g of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily

67 l leukotriene inflammation can differentiate LABA step-up responses from responses to LTRA or ICS ste

68 Patients were instructed to discontinue LABAs at week 4 and to taper and discontinue inhaled glu

69 Effect on Exacerbations in Patients on Dual [LABA/ICS] Therapy) trial (NCT01443845), participants age

70 ns are associated with adverse events during LABA therapy and should be evaluated in large clinical t

71 ave uncontrolled, persistent symptoms during LABA treatment (p=0.008-0.04).

72 with a differential FEV(1) response favoring LABA over ICS step-up therapy, whereas higher urinary le

73 hs (change in score from baseline, -0.68 for LABA + ICS vs -0.72 for tiotropium + ICS; between-group

74 in change in FEV1 at 12 months (0.003 L for LABA + ICS vs -0.018 L for tiotropium + ICS; between-gro

75 superiority of inhaled corticosteroid (ICS)/LABA combinations in asthma and chronic obstructive pulm

76 ICS+LABA therapy seems to be more effective than ICS+LTRA th

77 rtion of days covered, was higher in the ICS+LABA group compared with the ICS+LTRA group.

78 l setting subjects were more adherent to ICS+LABA therapy than ICS+LTRA therapy.

79 nd costs associated with ICS+LTRA versus ICS+LABA as step-up therapies for asthma.

80 s old) receiving ICS+LTRA therapy versus ICS+LABA therapy after a period of monotherapy with an ICS.

81 icant decreases in the use of fixed-dose ICS-LABA agents in children (-0.98 percentage points) and ad

82 combined with long-acting beta2-agonist (ICS/LABA) are standard treatments for asthma.

83 icosteroid and long-acting beta-agonist (ICS/LABA).

84 ICS alone, a PDE4 inhibitor alone, or an ICS/LABA combination therapy.

85 rapy alone, and 54% were treated with an ICS/LABA combination.

86 assess the relationship between ICS and ICS/LABA combination therapy and severe asthma exacerbations

87 ndividuals using ICS treatment alone and ICS/LABA combination therapy suggested that the overall prot

88 ICS and ICS/LABA exposure was estimated from pharmacy data for patie

89 Week 24 for triple therapy (n = 911) and ICS/LABA therapy (n = 899), mean changes from baseline in FE

90 ICS and ICS/LABA use was estimated for each day of follow-up to crea

91 5 mug; ELLIPTA inhaler) with twice-daily ICS/LABA therapy (budesonide/formoterol 400 mug/12 mug; Turb

92 related quality of life with twice-daily ICS/LABA therapy in patients with COPD.

93 ion rate with triple therapy versus dual ICS/LABA therapy (35% reduction; 95% CI, 14-51; P = 0.002).

94 tective effect was as good or better for ICS/LABA combination therapy when compared with ICS treatmen

95 scomfort with the middle or high dose of ICS/LABA combination agents under well technique (32 of BUD/

96 e is no evidence either ICS plus Tulo or ICS/LABA combination is better for elder patient.

97 was defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less.

98 trolled asthma patients receiving ICS or ICS/LABA were assessed for physical and psychiatric problems

99 ear (stable condition under the previous ICS/LABA).

100 Treatment with ICS/LABA fixed-dose combination therapy appeared to perform

101 gle-inhaler triple therapy compared with ICS/LABA therapy in patients with advanced COPD.

102 ICS/LABAs were switched to FP/FM-pMDI and slow and deep inha

103 in hospital admission rates were recorded in LABA-treated non-Hispanic white patients with the rare I

104 Combined use of an inhaled LABA with tiotropium bromide should provide important th

105 ce in vivo of an interaction between inhaled LABA and corticosteroid on GR nuclear translocation in h

106 LAMA/LABA fixed dose combinations (FDCs) provide the convenie

107 lly responsible for the increased benefit of LABA/LAMA combinations over single long-acting bronchodi

108 hance, sensitize, and prolong the effects of LABA/ICS combination therapies.

109 ults support the possibility that effects of LABA/LAMA combinations on hyperinflation, mucociliary cl

110 e findings do not support the superiority of LABA + ICS compared with tiotropium + ICS for black pati

111 e, continued favorable changes in the use of LABA agents were observed after the 2010 FDA regulatory

112 ies might have contributed to reduced use of LABA agents, as intended; however, their effect, indepen

113 ect of these regulatory activities on use of LABA-containing agents or other asthma medications.

114 score matching, there were 8712 new users of LABA-inhaled corticosteroid combination therapy and 3160

115 g beta-agonists (LABAs) (n = 3174), 1 RCT of LABAs and inhaled corticosteroids (ICS) (n = 1097), 5 RC

116 OPD hospitalization compared with new use of LABAs alone (difference in composite outcome at 5 years,

117 New use of LABAs and inhaled corticosteroids was associated with a

118 pitalizations [27.8%]) and 2129 new users of LABAs alone (1179 deaths [37.3%]; 950 COPD hospitalizati

119 id combination therapy and 3160 new users of LABAs alone who were followed up for median times of 2.7

120 outcome was observed among 5594 new users of LABAs and inhaled corticosteroids (3174 deaths [36.4%];

121 s over single long-acting bronchodilators or LABA/inhaled corticosteroids in decreasing exacerbation.

122 requency than either their monocomponents or LABA/inhaled corticosteroid combinations in patients at

123 ination LABAs and inhaled corticosteroids or LABAs alone.

124 ferential FEV(1) response favoring LTRA over LABA step-up therapy.

125 for patients receiving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per muL o

126 plus long-acting beta(2)-agonists (ICS plus LABA) and a history of two or more exacerbations in the

127 ids and long-acting beta2-agonists (ICS plus LABA) in the previous year.

128 ich are uncontrolled by high-dosage ICS plus LABA, and provide support for benralizumab to be an addi

129 tor antagonist (LTRAs; n = 354) or ICSs plus LABAs plus LTRAs (n = 569).

130 ted with inhaled corticosteroids (ICSs) plus LABAs but not for treatment with ICSs alone (n = 1758) o

131 he use of ADRB2 polymorphisms for predicting LABA treatment response is still limited and further pro

132 anticholinergic medication, newly prescribed LABA and inhaled corticosteroid combination therapy, com

133 tion therapy, compared with newly prescribed LABAs alone, was associated with a significantly lower r

134 th rare ADRB2 variants in patients receiving LABA therapy.

135 Patients receiving LABA with a rare ADRB2 variant had increased asthma-rela

136 hite and African American patients receiving LABAs with these rare variants had increased exacerbatio

137 Although preclinical studies suggest LABAs and LAMAs have antiinflammatory effects, such effe

138 ed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocort

139 combination of the LTRA montelukast and the LABA salmeterol could provide an effective therapeutic s

140 tation of GRE-dependent transcription by the LABA formoterol.

141 signed to receive, by inhalation, either the LABA indacaterol (110 mug) plus the LAMA glycopyrronium

142 periority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison).

143 al prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a f

144 MA glycopyrronium (50 mug) once daily or the LABA salmeterol (50 mug) plus the inhaled glucocorticoid

145 roflumilast N-oxide) each sensitized to the LABA, formoterol.

146 at baseline) predicted a better response to LABA step-up (P=0.009).

147 The response to LABA step-up therapy was most likely to be the best resp

148 White race predicted a better response to LABA step-up, whereas black patients were least likely t

149 be needed to predict individual responses to LABA step-up therapy.

150 2 variants modulate therapeutic responses to LABA therapy and contribute to rare, severe adverse even

151 tive biomarkers is crucial for understanding LABA safety.

152 matitis: OR 3.76 [2.14-6.61]), and drug use (LABA + ICS: 1.86 [1.27-2.74], antileukotrienes 4.83 [1.6

153 The proportions of asthmatic patients using LABA-containing products, inhaled corticosteroids (ICSs)

154 rences in the effects of tiotropium + ICS vs LABA + ICS (hazard ratio for time to first exacerbation,

155 ociated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with i

156 the rare, life-threatening events seen with LABA use.

157 erious asthma-related events associated with LABAs.

158 comitant use of inhaled glucocorticoids with LABAs mitigates those risks.

159 glucocorticosteroid therapy with or without LABAs.